JP2021502374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502374A5 JP2021502374A5 JP2020525946A JP2020525946A JP2021502374A5 JP 2021502374 A5 JP2021502374 A5 JP 2021502374A5 JP 2020525946 A JP2020525946 A JP 2020525946A JP 2020525946 A JP2020525946 A JP 2020525946A JP 2021502374 A5 JP2021502374 A5 JP 2021502374A5
- Authority
- JP
- Japan
- Prior art keywords
- nhch
- compound
- alkyl
- groups
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001769 aryl amino group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- -1 hydroxy, amino Chemical group 0.000 claims description 6
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 6
- 150000001345 alkine derivatives Chemical class 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- CUJNBCJGCYZRDB-CZIZESTLSA-N CCC(CC)(C(C=C1)=CCC1OCCN1CCOCC1)NC(/C(/C#N)=C/c1cccc(Cl)n1)=O Chemical compound CCC(CC)(C(C=C1)=CCC1OCCN1CCOCC1)NC(/C(/C#N)=C/c1cccc(Cl)n1)=O CUJNBCJGCYZRDB-CZIZESTLSA-N 0.000 description 1
- IJSFKUJWAMWFPX-MFDJWCQNSA-N CCC(CC)(CNC(/C(/C#N)=C/C(/C)=N/C=C\C#C)=O)c(cc1)ccc1OCCCN(CC)CC Chemical compound CCC(CC)(CNC(/C(/C#N)=C/C(/C)=N/C=C\C#C)=O)c(cc1)ccc1OCCCN(CC)CC IJSFKUJWAMWFPX-MFDJWCQNSA-N 0.000 description 1
- COOUJNZICIHBTQ-CZIZESTLSA-N CCC(CC)(c(cc1)ccc1OCCN(CC)CC)NC(/C(/C#N)=C/c1nc(Cl)ccc1)=O Chemical compound CCC(CC)(c(cc1)ccc1OCCN(CC)CC)NC(/C(/C#N)=C/c1nc(Cl)ccc1)=O COOUJNZICIHBTQ-CZIZESTLSA-N 0.000 description 1
- OHVLOCSGTNKDRQ-UHFFFAOYSA-N CCC(CC)(c(cc1)ccc1OCCN(CC)CC)NC(C(Cc1nc(Cl)ccc1)C#N)=O Chemical compound CCC(CC)(c(cc1)ccc1OCCN(CC)CC)NC(C(Cc1nc(Cl)ccc1)C#N)=O OHVLOCSGTNKDRQ-UHFFFAOYSA-N 0.000 description 1
- LSPJAWVBXQENHQ-CZIZESTLSA-N CCC(CC)(c(cc1)ccc1OCCN1CCNCC1)NC(/C(/C#N)=C/c1nc(Cl)ccc1)=O Chemical compound CCC(CC)(c(cc1)ccc1OCCN1CCNCC1)NC(/C(/C#N)=C/c1nc(Cl)ccc1)=O LSPJAWVBXQENHQ-CZIZESTLSA-N 0.000 description 1
- AECSUCBWBPEYDH-ZNTNEXAZSA-N CCC(CC)(c(cc1)ccc1OCCOCCN(CC)CCN(C)C)NC(/C(/C#N)=C/c1nc(Cl)ccc1)O Chemical compound CCC(CC)(c(cc1)ccc1OCCOCCN(CC)CCN(C)C)NC(/C(/C#N)=C/c1nc(Cl)ccc1)O AECSUCBWBPEYDH-ZNTNEXAZSA-N 0.000 description 1
- LQGFOYZSOMLIKG-XTQSDGFTSA-N CCC(CC)(c(cc1)ccc1OCCOCCN1CCN(C)CC1)NC(/C(/C#N)=C/c1nc(Cl)ccc1)=O Chemical compound CCC(CC)(c(cc1)ccc1OCCOCCN1CCN(C)CC1)NC(/C(/C#N)=C/c1nc(Cl)ccc1)=O LQGFOYZSOMLIKG-XTQSDGFTSA-N 0.000 description 1
- QAUNWJPVLQOUAG-AZPGRJICSA-N CCCN(C)CCNCCOCCOCCOc1ccc(C(CC)(CC)NC(/C(/C#N)=C/c2cccc(C)n2)=O)cc1 Chemical compound CCCN(C)CCNCCOCCOCCOc1ccc(C(CC)(CC)NC(/C(/C#N)=C/c2cccc(C)n2)=O)cc1 QAUNWJPVLQOUAG-AZPGRJICSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584591P | 2017-11-10 | 2017-11-10 | |
| US62/584,591 | 2017-11-10 | ||
| PCT/US2018/059975 WO2019094689A1 (en) | 2017-11-10 | 2018-11-09 | Caffeic acid derivatives for treating hyperproliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502374A JP2021502374A (ja) | 2021-01-28 |
| JP2021502374A5 true JP2021502374A5 (https=) | 2021-12-16 |
| JP7428642B2 JP7428642B2 (ja) | 2024-02-06 |
Family
ID=64664389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525946A Active JP7428642B2 (ja) | 2017-11-10 | 2018-11-09 | 過剰増殖性疾患を処置するためのコーヒー酸誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10703721B2 (https=) |
| EP (1) | EP3707125A1 (https=) |
| JP (1) | JP7428642B2 (https=) |
| KR (1) | KR20200085815A (https=) |
| CN (1) | CN111417625A (https=) |
| AU (1) | AU2018366270B2 (https=) |
| BR (1) | BR112020009219A2 (https=) |
| CA (1) | CA3081975A1 (https=) |
| EA (1) | EA202091164A1 (https=) |
| MX (1) | MX2020004871A (https=) |
| SG (1) | SG11202004230XA (https=) |
| TW (1) | TWI846678B (https=) |
| UA (1) | UA126821C2 (https=) |
| WO (1) | WO2019094689A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12539503B2 (en) | 2022-08-03 | 2026-02-03 | The University Of Toledo | Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| MXPA06006460A (es) * | 2003-12-11 | 2006-08-23 | Univ Texas | Compuestos para el tratamiento de enfermedades proliferativas celulares. |
| RU2456265C2 (ru) | 2006-03-31 | 2012-07-20 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам |
| US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| AU2009268841B2 (en) | 2008-07-08 | 2014-02-06 | Board Of Regents, The University Of Texas System | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS) |
| WO2011069141A2 (en) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| WO2012040527A2 (en) | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| JP2016537316A (ja) | 2013-10-10 | 2016-12-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| EP3148971A4 (en) | 2014-06-02 | 2017-10-25 | Pharmakea, Inc. | Deubiquitinase inhibitors |
-
2018
- 2018-11-08 TW TW107139731A patent/TWI846678B/zh active
- 2018-11-09 CA CA3081975A patent/CA3081975A1/en active Pending
- 2018-11-09 AU AU2018366270A patent/AU2018366270B2/en not_active Ceased
- 2018-11-09 MX MX2020004871A patent/MX2020004871A/es unknown
- 2018-11-09 US US16/185,669 patent/US10703721B2/en active Active
- 2018-11-09 EP EP18816306.7A patent/EP3707125A1/en active Pending
- 2018-11-09 EA EA202091164A patent/EA202091164A1/ru unknown
- 2018-11-09 BR BR112020009219-3A patent/BR112020009219A2/pt not_active IP Right Cessation
- 2018-11-09 KR KR1020207015972A patent/KR20200085815A/ko not_active Ceased
- 2018-11-09 JP JP2020525946A patent/JP7428642B2/ja active Active
- 2018-11-09 CN CN201880077894.0A patent/CN111417625A/zh active Pending
- 2018-11-09 WO PCT/US2018/059975 patent/WO2019094689A1/en not_active Ceased
- 2018-11-09 UA UAA202003449A patent/UA126821C2/uk unknown
- 2018-11-09 SG SG11202004230XA patent/SG11202004230XA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6824952B2 (ja) | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール | |
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP6783756B2 (ja) | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン | |
| JP2010514797A5 (https=) | ||
| CA2875025C (en) | Tricyclic inhibitors of poly(adp-ribose)polymerase | |
| JP2016128414A (ja) | ピリミジン誘導体の製造プロセス | |
| JP2017505790A (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| CN104010636B (zh) | 三环化合物、包含它们的组合物及其用途 | |
| JP6824906B2 (ja) | 併用療法 | |
| ES2814151T3 (es) | 1-Ciclohexilo-2-fenilaminobenzimidazoles como inhibidores de MIDH1 para el tratamiento de tumores | |
| EP3277276A1 (en) | Methods of administering glutaminase inhibitors | |
| JP2004517045A5 (https=) | ||
| JP2015502979A5 (https=) | ||
| JP2023510746A5 (https=) | ||
| TW202228693A (zh) | 用於治療癌症之組合療法 | |
| JP2023553534A5 (https=) | ||
| JP2022541545A5 (https=) | ||
| JP2007525494A5 (https=) | ||
| JP2019522681A5 (https=) | ||
| JP2021502374A5 (https=) | ||
| CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
| WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| JP2008528617A5 (https=) | ||
| JP2013525290A5 (https=) | ||
| JP2003505513A5 (https=) |